Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 18/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29788857 | 0.81 | CA2 (0.52) | CA2P2RX7 | |
| SCHEMBL7976991 | 0.77 | CYP2C9 (0.54) | P2RX7CYP2C9CYP2C19 | |
| SCHEMBL626266 | 0.76 | P2RX7 (0.49) | P2RX7 | |
| SCHEMBL7137210 | 0.76 | MAPK8 (0.49) | CYP2C9CYP2C19 | |
| SCHEMBL28170737 | 0.76 | P2RX7 (0.53) | CA2P2RX7 | |
| SCHEMBL5527359 | 0.76 | ALDH1A1 (0.59) | — | |
| SCHEMBL30572329 | 0.76 | MPO (0.46) | CA2P2RX7 | |
| SCHEMBL14431727 | 0.75 | CYP2C9 (0.47) | CYP2C9CYP2C19 | |
| SCHEMBL12366166 | 0.75 | P2RX7 (0.49) | CA2P2RX7 | |
| SCHEMBL2263310 | 0.75 | MCL1 (0.51) | CA2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466803-A | Compounds, salts thereof and methods for treating diseases | 阿卡蒂亚药品公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-111132976-B | Compounds, salts thereof and methods for treating diseases | 阿卡蒂亚药品公司 | 2023-08-22 | — | — | CN | disclosed |
| US-11345693-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345693-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, CYP27A1, CYP11B2 | CA2 1024/4885P2RX7 2574/4885CYP2C9 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.